418 related articles for article (PubMed ID: 32487192)
1. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
2. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
Liu AM; Xu Z; Shek FH; Wong KF; Lee NP; Poon RT; Chen J; Luk JM
PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
[TBL] [Abstract][Full Text] [Related]
3. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
[TBL] [Abstract][Full Text] [Related]
4. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
[TBL] [Abstract][Full Text] [Related]
5. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.
Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
[TBL] [Abstract][Full Text] [Related]
7. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma.
Ng KT; Yeung OW; Liu J; Li CX; Liu H; Liu XB; Qi X; Ma YY; Lam YF; Lau MY; Qiu WQ; Shiu HC; Lai MK; Lo CM; Man K
Int J Oncol; 2020 Oct; 57(4):956-966. PubMed ID: 32945373
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin
Roth GS; Teyssier Y; Abousalihac M; Seigneurin A; Ghelfi J; Sengel C; Decaens T
World J Gastroenterol; 2020 Jan; 26(3):324-334. PubMed ID: 31988592
[TBL] [Abstract][Full Text] [Related]
11. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
12. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
[TBL] [Abstract][Full Text] [Related]
13. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.
Yang W; Liu J; Hou L; Chen Q; Liu Y
Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
[TBL] [Abstract][Full Text] [Related]
15. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.
Wei X; Zhao L; Ren R; Ji F; Xue S; Zhang J; Liu Z; Ma Z; Wang XW; Wong L; Liu N; Shi J; Guo X; Roessler S; Zheng X; Ji J
Hepatology; 2021 Apr; 73(4):1381-1398. PubMed ID: 32609900
[TBL] [Abstract][Full Text] [Related]
16. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
Soliman MH; Ragheb MA; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):246-253. PubMed ID: 32416702
[TBL] [Abstract][Full Text] [Related]
18. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
19. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma.
Sciarra A; Ronot M; Di Tommaso L; Raschioni C; Castera L; Belghiti J; Bedossa P; Vilgrain V; Roncalli M; Paradis V
Liver Int; 2015 Nov; 35(11):2466-73. PubMed ID: 25865109
[TBL] [Abstract][Full Text] [Related]
20. Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway.
Liu B; Jin J; Zhang Z; Zuo L; Jiang M; Xie C
Biochem Cell Biol; 2019 Aug; 97(4):397-405. PubMed ID: 30475643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
